Summary
KW-2149 is a new mitomycin C (MMC) analog, forming DNA-DNA and DNA-protein crosslinking 20-fold more effectively than MMC. Because of its equal or superiorin vitro andin vivo activity compared to MMC, a phase I study was initiated with an intravenous bolus injection every three weeks. This study was interrupted after dose escalation from 5 mg/m2 to 100 mg/m2 because of subacute and dose dependent pulmonary toxicity. Because of the lack of other end-organ toxicity, the moderate hematological toxicity and the observed antitumor effect, a second phase I study was initiated with a 24 hour continuous infusion. The starting dose was 50 mg/m2 and further escalation depended on observed pulmonary toxicity. Four patients were entered into this study and they received in total 17 courses. Toxicity was again mainly restricted to the lungs with one patient suffering grade 2 dyspnoe and another one grade 1 dyspnoe. Three patients had a substantial change in the carbon monoxide (CO) diffusion capacity. Pharmacokinetic data from these patients showed very low plasma levels both for KW-2149, as for both known metabolites M-16 and M-18.
This study demonstrates that pulmonary toxicity continues to occur with KW-2149, in spite of the assurance of low plasma levels of both the parent compound and the known metabolites.
The interesting activity of this compound has stimulated further in-depth research towards mechanisms of pulmonary toxicity and means of preventing them.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kono M, Saitoh Y, Kasai M, Sato A, Shirahata K, Morimoto M, Ashizawa T: Synthesis and antitumor activity of a novel water soluble mitomycin analog; 7-N-(2-((2-(γ-L-glutamylamino)ethyl)dithio)ethyl)mitomycin C. Chem Pharm Bull 37:1128–1130, 1989
Iyengar BS, Sami SM, Remers WA, Bradner WT, Sehurig JE: Mitomycin C and Porfiromycin analogues with substituted ethylamines at position 7. J Med Chem 26:16–20, 1983
Iyengar BS, Sami SM, Tarnow SE, Remers WA, Bradner WT: Mitomycin C analogues with secundary amines at position 7. J Med Chem 26:1453–1457, 1983
Sami SM, Iyengar BS, Tarnow SE, Remers WA, Bradner WT, Schurig JE: Mitomycin C analogues with aryl substituents on the 7-amino group. J Med Chem 27:701–708, 1984
Tomasz M, Lipman R: Reductive metabolism and alkylating activity of mitomycin C induced by rat liver microsomes. Biochemistry 20:5056–5061, 1981
Morimoto M, Ashizawa T, Ohno H, Azuma M, Kobayashi E, Okabe M, Gomi K, Kono M, Saitoh Y, Kanda Y, Arai H, Sato A, Kasai M, Tsuruo T: Antitumor activity of 7-N-((2-((2-(γ-L-glutamylamino)ethyl)dithio) ethyl))-mitomycin C. Cancer Res 51:110–115, 1991
Kobayashi S, Ushiki J, Takai K, Okumura S, Kono M, Kasai M, Gomi K, Morimoto M, Ueno H, Hirata T: Disposition and metabolism of KW-2149, a novel anticancer agent. Cancer Chemother Pharmacol 32:143–150, 1993
Dirix LY, Gheuens EEO, Van Der Heyden S, Van Oosterom AT, De Bruijn EA: Cytotoxic activity of 7-N-(2-((2-(γ-L-glutamylamino)-thyl)dithio)ethyl)mitomycin C and metabolites in cell lines with different resistance patterns. Anti-Cancer Drugs 5:343–354, 1994
Kobayashi E, Okabe M, Kono M, Arai H, Asai M, Gomi K, Lee JH, Inaba M, Tsuruo T: Comparison of uptake of mitomycin C and KW-2149 by murine P388 leukemia cells sensitive or resistant to mitomycin C. Cancer Chemother Pharmacol 32:20–24, 1993
Ashizawa T, Okabe M, Gomi K, Hirata T: Reduced bone marrow toxicity of KW-2149, a mitomycin C derivative, in mice. Anti-Cancer Drugs 4:181–188, 1993
Dirix L, Catimel G, Koier I, Prové A, Schrijvers D, Joossens E, De Bruijn E, Ardiet C, Evene E, Dumortier A, Clavel M, Van Oosterom AT: Phase I and pharmaco-kinetic study of a novel mitomycin C analog KW-2149. Anti-Cancer Drugs 6:53–63, 1995
WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication N° 48. Geneva, Switserland, World Health Organization, 1979
Pattyn G, Van Oosterom AT, De Bruijn EA, Tjaden UR: Determination of the new anticancer agent KW-2149, 7-N-(2-((2-(γ-L glutamylamino)ethyl)dithio)ethyl) mitomycin C, an analogue of mitomycin C. J Chromatogr 564:352–354, 1991
Doll DC, Weiss RB, Issell BF: Mitomycin: ten years after approval for marketing. J Clin Oncol 3:276–286, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dirix, L., Catimel, G., Verdonk, R. et al. Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion. Invest New Drugs 13, 133–136 (1995). https://doi.org/10.1007/BF00872861
Issue Date:
DOI: https://doi.org/10.1007/BF00872861